KIF5B-RET Oncoprotein Signals Through a Multi-kinase Signaling Hub

Overview

Journal Cell Rep

Publisher Cell Press

Specialties Biology
Cell Biology
Molecular Biology

Date 2017 Sep 7

PMID 28877471

Citations 29

Authors

Tirtha Kamal Das

Ross Leigh Cagan

Affiliations

Soon will be listed here.

Abstract

Gene fusions are increasingly recognized as important cancer drivers. The KIF5B-RET gene has been identified as a primary driver in a subset of lung adenocarcinomas. Targeting human KIF5B-RET to epithelia in Drosophila directed multiple aspects of transformation, including hyperproliferation, epithelial-to-mesenchymal transition, invasion, and extension of striking invadopodia-like processes. The KIF5B-RET-transformed human bronchial cell line showed similar aspects of transformation, including invadopodia-like processes. Through a combination of genetic and biochemical studies, we demonstrate that the kinesin and kinase domains of KIF5B-RET act together to establish an emergent microtubule and RAB-vesicle-dependent RET-SRC-EGFR-FGFR signaling hub. We demonstrate that drugs designed to inhibit RET alone work poorly in KIF5B-RET-transformed cells. However, combining the RET inhibitor sorafenib with drugs that target EGFR, microtubules, or FGFR led to strong efficacy in both Drosophila and human cell line KIF5B-RET models. This work demonstrates the utility of exploring the full biology of fusions to identify rational therapeutic strategies.

Citing Articles

Safety, pharmacokinetics and efficacy of HA121-28 in patients with advanced solid tumors and RET fusion-positive non-small-cell lung cancer: a multicenter, open-label, single-arm phase 1/2 trial.

Ruan D, Huang W, Li Y, Zhao Y, Shi Y, Jia Y Signal Transduct Target Ther. 2025; 10(1):62.

PMID: 40016191 PMC: 11868595. DOI: 10.1038/s41392-025-02155-5.

Exploring the versatility of as a model organism in biomedical research: a comprehensive review.

Atoki A, Aja P, Shinkafi T, Ondari E, Adeniyi A, Fasogbon I Fly (Austin). 2024; 19(1):2420453.

PMID: 39722550 PMC: 11702942. DOI: 10.1080/19336934.2024.2420453.

Side Chain Investigation of Imidazopyridazine as a Hinge Binder for Targeting Actionable Mutations of RET Kinase.

Maturi A, Sastry K, Kumar S, Pogaku V, Kwon H, Ahn S ACS Med Chem Lett. 2024; 15(9):1566-1574.

PMID: 39291010 PMC: 11403754. DOI: 10.1021/acsmedchemlett.4c00287.

Differences in Genomic Alterations and Accumulations of Heavy Metals Between Advanced Non-small Cell Lung Cancer Patients with and without Bone Metastasis.

Yao Z, Jiang H, Wang F, Fan Z, Zhang Y, Mou S J Cancer. 2024; 15(13):4205-4218.

PMID: 38947377 PMC: 11212080. DOI: 10.7150/jca.95191.

The efficacy and safety of selective RET inhibitors in RET fusion-positive non-small cell lung cancer: a meta-analysis.

Ke J, Huang S, Jing Z, Duan M Invest New Drugs. 2023; 41(5):768-776.

PMID: 37603207 PMC: 10560178. DOI: 10.1007/s10637-023-01390-3.

References

Plaza-Menacho I, Barnouin K, Goodman K, Martinez-Torres R, Borg A, Murray-Rust J . Oncogenic RET kinase domain mutations perturb the autophosphorylation trajectory by enhancing substrate presentation in trans. Mol Cell. 2014; 53(5):738-51. PMC: 3988870. DOI: 10.1016/j.molcel.2014.01.015. View

Buszczak M, Paterno S, Lighthouse D, Bachman J, Planck J, Owen S . The carnegie protein trap library: a versatile tool for Drosophila developmental studies. Genetics. 2006; 175(3):1505-31. PMC: 1840051. DOI: 10.1534/genetics.106.065961. View

Roch F, Noll E, Baonza A, Duffy J, Perrimon N . A temporal switch in DER signaling controls the specification and differentiation of veins and interveins in the Drosophila wing. Development. 1999; 126(24):5739-47. DOI: 10.1242/dev.126.24.5739. View

Sato M, Vaughan M, Girard L, Peyton M, Lee W, Shames D . Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. Cancer Res. 2006; 66(4):2116-28. DOI: 10.1158/0008-5472.CAN-05-2521. View

Vaishnavi A, Schubert L, Rix U, Marek L, Le A, Keysar S . EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases. Cancer Res. 2017; 77(13):3551-3563. PMC: 5516930. DOI: 10.1158/0008-5472.CAN-17-0109. View

Liu Z, Falola J, Zhu X, Gu Y, Kim L, Sarosi G . Antiproliferative effects of Src inhibition on medullary thyroid cancer. J Clin Endocrinol Metab. 2004; 89(7):3503-9. DOI: 10.1210/jc.2003-031917. View

Gautschi O, Milia J, Filleron T, Wolf J, Carbone D, Owen D . Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. J Clin Oncol. 2017; 35(13):1403-1410. PMC: 5559893. DOI: 10.1200/JCO.2016.70.9352. View

Dar A, Das T, Shokat K, Cagan R . Chemical genetic discovery of targets and anti-targets for cancer polypharmacology. Nature. 2012; 486(7401):80-4. PMC: 3703503. DOI: 10.1038/nature11127. View

Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S . RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012; 18(3):378-81. DOI: 10.1038/nm.2658. View

10.

Rothenberg S, Concannon K, Cullen S, Boulay G, Turke A, Faber A . Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways. Elife. 2015; 4. PMC: 4384750. DOI: 10.7554/eLife.06132. View

11.

Lin C, Wang S, Xie W, Zheng R, Gan Y, Chang J . Apatinib inhibits cellular invasion and migration by fusion kinase KIF5B-RET via suppressing RET/Src signaling pathway. Oncotarget. 2016; 7(37):59236-59244. PMC: 5312308. DOI: 10.18632/oncotarget.10985. View

12.

Clark E, Whigham A, Yarbrough W, Weaver A . Cortactin is an essential regulator of matrix metalloproteinase secretion and extracellular matrix degradation in invadopodia. Cancer Res. 2007; 67(9):4227-35. DOI: 10.1158/0008-5472.CAN-06-3928. View

13.

Gibson N, Tolbert L, Oland L . Activation of glial FGFRs is essential in glial migration, proliferation, and survival and in glia-neuron signaling during olfactory system development. PLoS One. 2012; 7(4):e33828. PMC: 3320908. DOI: 10.1371/journal.pone.0033828. View

14.

Setou M, Tanaka Y, Kanai Y, Takei Y, Kawagishi M, Hirokawa N . Glutamate-receptor-interacting protein GRIP1 directly steers kinesin to dendrites. Nature. 2002; 417(6884):83-7. DOI: 10.1038/nature743. View

15.

Lam E, Ringel M, Kloos R, Prior T, Knopp M, Liang J . Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol. 2010; 28(14):2323-30. PMC: 2881718. DOI: 10.1200/JCO.2009.25.0068. View

16.

Jemal A, Center M, DeSantis C, Ward E . Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010; 19(8):1893-907. DOI: 10.1158/1055-9965.EPI-10-0437. View

17.

Drilon A, Rekhtman N, Arcila M, Wang L, Ni A, Albano M . Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. Lancet Oncol. 2016; 17(12):1653-1660. PMC: 5143197. DOI: 10.1016/S1470-2045(16)30562-9. View

18.

Wright T, Petersen J . Treatment of recurrent dermatofibrosarcoma protuberans with imatinib mesylate, followed by Mohs micrographic surgery. Dermatol Surg. 2007; 33(6):741-4. DOI: 10.1111/j.1524-4725.2007.33154.x. View

19.

Apsel B, Blair J, Gonzalez B, Nazif T, Feldman M, Aizenstein B . Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008; 4(11):691-9. PMC: 2880455. DOI: 10.1038/nchembio.117. View

20.

Levinson S, Cagan R . Drosophila Cancer Models Identify Functional Differences between Ret Fusions. Cell Rep. 2016; 16(11):3052-3061. PMC: 5858711. DOI: 10.1016/j.celrep.2016.08.019. View